Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for Q32 Bio Inc. as of June 30, 2025 is -54.74 MM.
- The net income for Q32 Bio Inc. as of June 30, 2025 is -52.30 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -54.74 | -52.30 | |
2025-03-31 | -62.56 | -59.79 | |
2024-12-31 | -66.10 | -47.73 | |
2024-09-30 | -14.66 | -77.39 | -60.61 |
2024-06-30 | -12.80 | -66.37 | -57.05 |
2024-03-31 | -9.60 | -55.73 | -45.88 |
2023-12-31 | -6.65 | -48.26 | -53.74 |
2023-09-30 | 11.79 | -30.36 | -36.36 |
2022-12-31 | 6.65 | -39.23 | -42.81 |
2021-12-31 | -36.69 | -37.56 |
Income Statement: EPS
- The earnings per share basic for Q32 Bio Inc. as of June 30, 2025 is -4.29.
- The earnings per share diluted for Q32 Bio Inc. as of June 30, 2025 is -4.29.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -4.29 | -4.29 |
2025-03-31 | -4.93 | -4.93 |
2024-12-31 | -5.12 | -6.58 |
2024-09-30 | -9.55 | -12.04 |
2024-06-30 | -16.70 | -21.33 |
2024-03-31 | -89.65 | -120.53 |
2023-12-31 | -153.96 | -153.96 |
2023-09-30 | -17.78 | -17.78 |
2022-12-31 | -6.09 | |
2021-12-31 | -5.81 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Q32 Bio Inc. as of June 30, 2025 is -54.08 MM.
- The cash from investing activities for Q32 Bio Inc. as of June 30, 2025 is 9.94 MM.
- The cash from financing activities for Q32 Bio Inc. as of June 30, 2025 is 1.31 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -54.08 | 9.94 | 1.31 |
2025-03-31 | -65.65 | 19.83 | -4.21 |
2024-12-31 | -67.72 | 19.93 | 95.14 |
2024-09-30 | -67.00 | 19.93 | 94.90 |
2024-06-30 | -31.58 | 9.98 | 94.20 |
2024-03-31 | -20.73 | 0.10 | 99.74 |
2023-12-31 | -18.68 | -0.01 | 0.41 |
2023-09-30 | 1.56 | 0.01 | 17.00 |
2022-12-31 | -10.96 | -2.47 | 30.07 |
2021-12-31 | -32.98 | -0.16 | 20.11 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for Q32 Bio Inc. as of June 30, 2025 is -0.30.
- The p/book for Q32 Bio Inc. as of June 30, 2025 is -4.50.
- The p/tbv for Q32 Bio Inc. as of June 30, 2025 is -4.50.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -0.30 | -4.50 | -4.50 |
2025-03-31 | -0.44 | 3.68 | 3.68 |
2024-12-31 | 2.07 | 2.07 | |
2024-09-30 | -9.72 | 16.55 | 16.55 |
2024-06-30 | -3.97 | 3.73 | 3.73 |
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2022-12-31 | |||
2021-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Q32 Bio Inc. as of June 30, 2025 is 1.72.
- The ebit (3y)/ev for Q32 Bio Inc. as of June 30, 2025 is 1.51.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | 1.72 | 1.51 |
2025-03-31 | 1.33 | 1.27 |
2024-12-31 | 1.85 | 1.63 |
2024-09-30 | -0.12 | -0.09 |
2024-06-30 | -0.23 | -0.21 |
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2022-12-31 | ||
2021-12-31 |
Management Effectiveness
- The roa for Q32 Bio Inc. as of June 30, 2025 is -0.48.
- The roe for Q32 Bio Inc. as of June 30, 2025 is -1.78.
- The roic for Q32 Bio Inc. as of June 30, 2025 is -4.04.
- The croic for Q32 Bio Inc. as of June 30, 2025 is -3.38.
- The ocroic for Q32 Bio Inc. as of June 30, 2025 is -4.44.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-06-30 | -0.48 | -1.78 | -4.04 | -3.38 | -4.44 |
2025-03-31 | -0.31 | -0.98 | -1.44 | 1.42 | -2.04 |
2024-12-31 | -1.29 | -1.36 | 1.07 | -1.50 | |
2024-09-30 | -1.06 | -0.95 | 1.21 | -0.53 | |
2024-06-30 | -0.74 | -0.62 | 1.07 | -0.28 | |
2024-03-31 | -0.59 | -7.70 | 3.93 | 0.33 | |
2023-12-31 | -7.70 | 3.93 | 0.33 | ||
2023-09-30 | |||||
2022-12-31 | |||||
2021-12-31 | -1.38 | -0.48 | -1.21 |
Gross Margins
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-06-30 | |||
2025-03-31 | 4.28 | 3.26 | 4.51 |
2024-12-31 | 4.13 | 4.13 | 5.28 |
2024-09-30 | 4.05 | 4.46 | 5.18 |
2024-06-30 | 4.51 | 4.78 | 5.81 |
2024-03-31 | -1.76 | -3.08 | -2.57 |
2023-12-31 | -1.76 | -3.08 | -2.57 |
2023-09-30 | -4.38 | -6.44 | -5.90 |
2022-12-31 | |||
2021-12-31 |
Identifiers and Descriptors
Central Index Key (CIK) | 1661998 |
Industry Groups
SIC 2834 - Pharmaceutical Preparations |